Literature DB >> 9511933

Cystic fibrosis: a disease of altered protein folding.

B H Qu1, E Strickland, P J Thomas.   

Abstract

Cystic fibrosis (CF) is caused by mutations in the gene that encodes the cystic fibrosis transmembrane conductance regulator, CFTR. Previously we demonstrated that the common delta F508 mutation in the first nucleotide binding domain (NBD1) alters the ability of the domain to fold into a functional three-dimensional structure, providing a molecular explanation for the observation that the mutant CFTR is retained in the endoplasmic reticulum and does not traffic to the apical membrane of affected epithelial cells. Notably, when conditions are altered to promote folding of the mutant protein, it can assume a functional conformation. Correcting the folding defect may have therapeutic benefit for the treatment of cystic fibrosis. Here we summarize these results and discuss the implications in vitro folding studies have for understanding the pathobiology of CF.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9511933     DOI: 10.1023/a:1022439108101

Source DB:  PubMed          Journal:  J Bioenerg Biomembr        ISSN: 0145-479X            Impact factor:   2.945


  56 in total

1.  Altered chloride ion channel kinetics associated with the delta F508 cystic fibrosis mutation.

Authors:  W Dalemans; P Barbry; G Champigny; S Jallat; K Dott; D Dreyer; R G Crystal; A Pavirani; J P Lecocq; M Lazdunski
Journal:  Nature       Date:  1991 Dec 19-26       Impact factor: 49.962

2.  Chloride conductance expressed by delta F508 and other mutant CFTRs in Xenopus oocytes.

Authors:  M L Drumm; D J Wilkinson; L S Smit; R T Worrell; T V Strong; R A Frizzell; D C Dawson; F S Collins
Journal:  Science       Date:  1991-12-20       Impact factor: 47.728

3.  Association between calnexin and a secretion-incompetent variant of human alpha 1-antitrypsin.

Authors:  A Le; J L Steiner; G A Ferrell; J C Shaker; R N Sifers
Journal:  J Biol Chem       Date:  1994-03-11       Impact factor: 5.157

4.  Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA.

Authors:  J R Riordan; J M Rommens; B Kerem; N Alon; R Rozmahel; Z Grzelczak; J Zielenski; S Lok; N Plavsic; J L Chou
Journal:  Science       Date:  1989-09-08       Impact factor: 47.728

Review 5.  Altered protein folding may be the molecular basis of most cases of cystic fibrosis.

Authors:  P J Thomas; Y H Ko; P L Pedersen
Journal:  FEBS Lett       Date:  1992-11-02       Impact factor: 4.124

6.  The common variant of cystic fibrosis transmembrane conductance regulator is recognized by hsp70 and degraded in a pre-Golgi nonlysosomal compartment.

Authors:  Y Yang; S Janich; J A Cohn; J M Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-15       Impact factor: 11.205

7.  Chloride impermeability in cystic fibrosis.

Authors:  P M Quinton
Journal:  Nature       Date:  1983-02-03       Impact factor: 49.962

8.  Identification of an ion channel-forming motif in the primary structure of CFTR, the cystic fibrosis chloride channel.

Authors:  M Oblatt-Montal; G L Reddy; T Iwamoto; J M Tomich; M Montal
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-15       Impact factor: 11.205

9.  The cystic fibrosis transmembrane conductance regulator. Effects of the most common cystic fibrosis-causing mutation on the secondary structure and stability of a synthetic peptide.

Authors:  P J Thomas; P Shenbagamurthi; J Sondek; J M Hullihen; P L Pedersen
Journal:  J Biol Chem       Date:  1992-03-25       Impact factor: 5.157

10.  Intracellular turnover of cystic fibrosis transmembrane conductance regulator. Inefficient processing and rapid degradation of wild-type and mutant proteins.

Authors:  C L Ward; R R Kopito
Journal:  J Biol Chem       Date:  1994-10-14       Impact factor: 5.157

View more
  21 in total

Review 1.  Rescuing protein conformation: prospects for pharmacological therapy in cystic fibrosis.

Authors:  Marina S Gelman; Ron R Kopito
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

Review 2.  Frontiers in research on cystic fibrosis: understanding its molecular and chemical basis and relationship to the pathogenesis of the disease.

Authors:  Y H Ko; P L Pedersen
Journal:  J Bioenerg Biomembr       Date:  1997-10       Impact factor: 2.945

Review 3.  Proteotoxicity and cardiac dysfunction.

Authors:  Patrick M McLendon; Jeffrey Robbins
Journal:  Circ Res       Date:  2015-05-22       Impact factor: 17.367

4.  FK506 binding protein 8 peptidylprolyl isomerase activity manages a late stage of cystic fibrosis transmembrane conductance regulator (CFTR) folding and stability.

Authors:  Darren M Hutt; Daniela Martino Roth; Monica A Chalfant; Robert T Youker; Jeanne Matteson; Jeffrey L Brodsky; William E Balch
Journal:  J Biol Chem       Date:  2012-04-02       Impact factor: 5.157

5.  Ubiquitin C-terminal hydrolase-L1 protects cystic fibrosis transmembrane conductance regulator from early stages of proteasomal degradation.

Authors:  Mark J Henderson; Neeraj Vij; Pamela L Zeitlin
Journal:  J Biol Chem       Date:  2010-02-10       Impact factor: 5.157

6.  Defective trafficking and function of KATP channels caused by a sulfonylurea receptor 1 mutation associated with persistent hyperinsulinemic hypoglycemia of infancy.

Authors:  E A Cartier; L R Conti; C A Vandenberg; S L Shyng
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

7.  Disulfide bond effects on protein stability: designed variants of Cucurbita maxima trypsin inhibitor-V.

Authors:  M Zavodszky; C W Chen; J K Huang; M Zolkiewski; L Wen; R Krishnamoorthi
Journal:  Protein Sci       Date:  2001-01       Impact factor: 6.725

Review 8.  Emergent properties of proteostasis in managing cystic fibrosis.

Authors:  William E Balch; Daniela M Roth; Darren M Hutt
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-02-01       Impact factor: 10.005

9.  Carbamazepine as a novel small molecule corrector of trafficking-impaired ATP-sensitive potassium channels identified in congenital hyperinsulinism.

Authors:  Pei-Chun Chen; Erik M Olson; Qing Zhou; Yelena Kryukova; Heidi M Sampson; David Y Thomas; Show-Ling Shyng
Journal:  J Biol Chem       Date:  2013-06-06       Impact factor: 5.157

Review 10.  The proteostasis boundary in misfolding diseases of membrane traffic.

Authors:  Darren M Hutt; Evan T Powers; William E Balch
Journal:  FEBS Lett       Date:  2009-08-20       Impact factor: 4.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.